Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mainstay Set To Launch ReActiv8 Neurostimulator In Germany

This article was originally published in Clinica

Executive Summary

Mainstay Medical is ready to launch its ReActiv8 neurostimulator, starting in Germany, now that the implantable device has a CE mark for the treatment of chronic back pain, the company announced May 25.

You may also be interested in...

Mainstay Medical Wins First ReActiv8 Neurostimulation Implant Sale

Mainstay Medical has sold its first ReActiv8 neurostimulator implant in Germany. The implant was performed by an orthopedic surgeon at the Catholic Hospital Koblenz-Montabaur in Koblenz, Germany.

Starts & Stops: Back Pain Neurostim Device, Prostatic Stent Move Into Pivotal Trials

Starts & Stops is a regular feature highlighting the Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions from the previous month. August's selection includes a few emerging innovators advancing into large pivotal trials for their game-changing technologies.

Pixium's IRIS II CE Mark Stokes Retinal Implant Rivalry

Competition in the retinal implant market heats up as Pixium CE marks its second-generation bionic vision system, designed to offer key advantages including higher resolution and explantability.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts